| 5.4848 -0.275 (-4.78%) | 05-14 15:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.49 |
1-year : | 8.19 |
| Resists | First : | 6.41 |
Second : | 7.01 |
| Pivot price | 5.81 |
|||
| Supports | First : | 5.44 |
Second : | 4.53 |
| MAs | MA(5) : | 5.78 |
MA(20) : | 5.96 |
| MA(100) : | 7.02 |
MA(250) : | 6.48  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 17 |
D(3) : | 26.4 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 10.98 | Low : | 2.51 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LXEO ] has closed above bottom band by 10.4%. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6 - 6.03 | 6.03 - 6.05 |
| Low: | 5.55 - 5.58 | 5.58 - 5.61 |
| Close: | 5.71 - 5.76 | 5.76 - 5.8 |
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Mon, 11 May 2026
Lexeo Therapeutics (NASDAQ: LXEO) posts lower Q1 loss with $227.6M cash - Stock Titan
Mon, 11 May 2026
Lexeo (Nasdaq: LXEO) trims Q1 loss and advances pivotal cardiac gene therapy plans - Stock Titan
Thu, 30 Apr 2026
Dr. Laura Sepp-Lorenzino joins Lexeo Therapeutics (LXEO) board and science committee - Stock Titan
Thu, 30 Apr 2026
Lexeo Therapeutics (LXEO) director receives 50,000 stock options at $5.81 strike - Stock Titan
Tue, 25 Nov 2025
LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView
Thu, 06 Nov 2025
Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 74 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 112.6 (%) |
| Shares Short | 12,600 (K) |
| Shares Short P.Month | 11,800 (K) |
| EPS | -1.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.9 % |
| Return on Equity (ttm) | -55 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.87 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -99 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -2.98 |
| PEG Ratio | 0 |
| Price to Book value | 1.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|